drugset / Trial / NCT07158996
A Study of Cizutamig in Systemic Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with SSc.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2026-12-01
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cizutamig | Protein / enzyme biologic | — | — |